These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, Thompson D, Freund KB. Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648 [Abstract] [Full Text] [Related]
23. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA, Post-Injection Endophthalmitis (PIE) Study Team. Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087 [Abstract] [Full Text] [Related]
24. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. Cleary CA, Sharaznayan D, Hickey-Dwyer M. Ir Med J; 2011 May; 104(5):146-9. PubMed ID: 21736091 [Abstract] [Full Text] [Related]
26. [Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration]. Kloos P, Niederberger H, Valmaggia C. Klin Monbl Augenheilkd; 2011 Apr; 228(4):340-4. PubMed ID: 21484643 [Abstract] [Full Text] [Related]
27. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Abouammoh M, Sharma S. Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262 [Abstract] [Full Text] [Related]
33. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration. Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E. Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782 [Abstract] [Full Text] [Related]
34. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Melamud A, Stinnett S, Fekrat S. Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144 [Abstract] [Full Text] [Related]
35. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Arch Ophthalmol; 2010 Oct; 128(10):1273-9. PubMed ID: 20937996 [Abstract] [Full Text] [Related]